<DOC>
	<DOCNO>NCT01653249</DOCNO>
	<brief_summary>This study consist 300 woman age 18-50 year . The study show new therapeutic human papillomavirus ( HPV ) vaccine design regress precancerous condition call high-grade squamous intraepithelial neoplasia ( HSIL ) safe . HPV know cause cervical , vaginal , oral , anal cancer . This novel vaccine consist synthetically make fragment HPV protein call E6 yeast extract call CandinÂ® . Previous study reveal immune response E6 important fighting HPV . We also know inject Candin anti-HPV effect since use treat common wart cause different type HPV . The current standard treatment HSIL loop electrical excision procedure ( LEEP ) . The immune system part body fight infection cancer . This research study also examine immune response vaccine effectiveness regress HSIL . Volunteers would eligible enroll study recent Papanicolaou ( Pap ) smear result indicate HSIL `` Can rule HSIL '' , meet inclusion/exclusion criterion . Subjects eligible receive vaccination biopsy confirms HSIL . A series four vaccination give roughly 3 week apart , LEEP perform end study approximately 12 week last vaccination .</brief_summary>
	<brief_title>A Phase I Clinical Trial HPV Therapeutic Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 1850 year Had recent Pap smear result consistent HSIL `` rule HSIL '' HSIL biopsy Untreated HSIL `` Can rule HSIL '' Able provide inform consent Certain physical exam blood component parameter within acceptable range Willingness able comply requirement protocol good command English language History disease treatment cause immunosuppression ( e.g. , cancer , HIV , organ transplant , autoimmune disease ) Being pregnant attempt pregnant within period enrollment Breast feeding planning breast feed within period enrollment Allergy Candida antigen History severe asthma require emergency room visit hospitalization Current use betablocker medication ( may respond epinephrine case anaphylaxis ) If opinion Principal Investigator Investigators , best interest patient enter study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>human papillomavirus ( HPV )</keyword>
	<keyword>vaccine</keyword>
	<keyword>treatment</keyword>
</DOC>